Search Browse Earnings

HARROW, INC.

Nasdaq:HROW

Pharmaceutical Preparations·NASHVILLE, TN

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

HARROW, INC. — SlamSEC

CEO

Baum Mark L

CFO

Boll Andrew R.

Revenue

$130.2M

+0.0% YoY

FY 2025

Adj. EBITDA

$2.0M

1.5% margin

FY 2025

Net Income

-$24.4M

-18.7% margin

FY 2025

EPS (Diluted)

-$0.75

FY 2025

Stock Price

$36.34

+0.5%

2026-03-06

52W Range

$20.85 – $54.85

P/E Ratio

-48.5x

Market Cap

$1.4B

Cash

$47.2M

FY 2025

Total Debt

$253.9M

FY 2025

Net Debt

$206.7M

FY 2025

Enterprise Value

$1.6B

Debt / EBITDA

105.4x

FY 2025

EV / EBITDA

795.3x

Employees

—